Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State
mi
from
Columbus, OH
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State
mi
from
Columbus, OH
Click here to add this to my saved trials
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
South Texas Oncology and Hematology, PA South Texas Oncology (2)
mi
from
San Antonio, TX
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
South Texas Oncology and Hematology, PA South Texas Oncology (2)
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
Stanford University Medical Center Stanford
mi
from
Stanford, CA
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
Stanford University Medical Center Stanford
mi
from
Stanford, CA
Click here to add this to my saved trials
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
University of California at Los Angeles UCLA SC
mi
from
Los Angeles, CA
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
University of California at Los Angeles UCLA SC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 2
mi
from
Madison, WI
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 2
mi
from
Madison, WI
Click here to add this to my saved trials
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
Vanderbilt University Medical Center Vanderbilt - Thompson Ln
mi
from
Nashville, TN
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
Vanderbilt University Medical Center Vanderbilt - Thompson Ln
mi
from
Nashville, TN
Click here to add this to my saved trials
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/27/2014
Yale University School of Medicine Yale Univ
mi
from
New Haven, CT
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/27/2014
Yale University School of Medicine Yale Univ
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)
A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Tampa, FL
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)
A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)
A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Boston, MA
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)
A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)
A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  3/28/2014
Clinical Research Facility
mi
from
Houston, TX
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)
A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 3/28/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated:  4/3/2014
TGen Clinical Research Services (TCRS)
mi
from
Scottsdale, AZ
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated: 4/3/2014
TGen Clinical Research Services (TCRS)
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated:  4/3/2014
Disney Family Cancer Center
mi
from
Burbank, CA
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated: 4/3/2014
Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated:  4/3/2014
Virginia Piper Cancer Institute (VPCI)
mi
from
Minneapolis, MN
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated: 4/3/2014
Virginia Piper Cancer Institute (VPCI)
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated:  4/3/2014
Virginia Mason Medical Center
mi
from
Seattle, WA
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated: 4/3/2014
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated:  4/3/2014
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated: 4/3/2014
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Click here to add this to my saved trials
Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer
iPC3 - Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer
Status: Enrolling
Updated:  4/8/2014
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer
iPC3 - Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer
Status: Enrolling
Updated: 4/8/2014
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer
Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer
Status: Enrolling
Updated:  4/9/2014
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer
Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer
Status: Enrolling
Updated: 4/9/2014
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Validity and Reliability of Outcome Measures in Patients With Cancer of the Head and Neck
The Validity and Reliability of the Six-Minute Walk Test, Ten-Meter Walk Test, 30 Second Chair Stand, Linear Analog Scale of Function, and the Modified Brief Fatigue Inventory in Patients With Cancer of the Head and Neck
Status: Enrolling
Updated:  4/10/2014
Mayo Clinic
mi
from
Phoenix, AZ
Validity and Reliability of Outcome Measures in Patients With Cancer of the Head and Neck
The Validity and Reliability of the Six-Minute Walk Test, Ten-Meter Walk Test, 30 Second Chair Stand, Linear Analog Scale of Function, and the Modified Brief Fatigue Inventory in Patients With Cancer of the Head and Neck
Status: Enrolling
Updated: 4/10/2014
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
A Phase I/II Trial of AMG 102 and Erlotinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/14/2014
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
A Phase I/II Trial of AMG 102 and Erlotinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/14/2014
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Alone or in Combination in Adult Subjects With Advanced Cancers
Status: Enrolling
Updated:  4/17/2014
Clinical Research Facility
mi
from
San Antonio, TX
A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Alone or in Combination in Adult Subjects With Advanced Cancers
Status: Enrolling
Updated: 4/17/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Banner Health
mi
from
Phoenix, AZ
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Banner Health
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Sutter Institute
mi
from
Sacramento, CA
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Sutter Institute
mi
from
Sacramento, CA
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Scripps
mi
from
San Diego, CA
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Scripps
mi
from
San Diego, CA
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Sansum Clinic
mi
from
Santa Barbara, CA
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Sansum Clinic
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Lahey Clinic
mi
from
Peabody, MA
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Lahey Clinic
mi
from
Peabody, MA
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Henry Ford Hospital
mi
from
Detroit, MI
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Rhode Island Hospital
mi
from
Providence, RI
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated:  4/21/2014
Avera Research Institute
mi
from
Sioux Falls, SD
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Status: Enrolling
Updated: 4/21/2014
Avera Research Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease
The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease
Status: Enrolling
Updated:  4/22/2014
St. Jude Children's Research Hospital
mi
from
Memphis, TN
The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease
The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease
Status: Enrolling
Updated: 4/22/2014
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Stanford, CA
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Tampa, FL
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Saint Louis, MO
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
New Brunswick, NJ
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Houston, TX
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated:  4/23/2014
Clinical Research Facility
mi
from
Milwaukee, WI
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Enrolling
Updated: 4/23/2014
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Protocol of Irinotecan for Carcinoma of the Lung
A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung
Status: Enrolling
Updated:  4/28/2014
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
A Protocol of Irinotecan for Carcinoma of the Lung
A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung
Status: Enrolling
Updated: 4/28/2014
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Birmingham, AL
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Tucson, AZ
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Burbank, CA
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Ft. Myers, FL
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Ft. Myers, FL
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
St. Petersburg, FL
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Ann Arbor, MI
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Las Vegas, NV
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
East Orange, NJ
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
East Orange, NJ
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Rochester, NY
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Chattanooga, TN
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Fort Worth, TX
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Houston, TX
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated:  4/29/2014
Clinical Research Facility
mi
from
Webster, TX
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Status: Enrolling
Updated: 4/29/2014
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials